Mabtech AB
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Mabtech AB - overview
Established
1986
Location
Stockholm, -, Sweden
Primary Industry
Biotechnology
About
Based in Nacka Strand, Sweden, and founded in 1986, Mabtech AB operates as a provider of monoclonal antibodies, kits, and instruments for immunoassays to the life sciences research community. In January 2024, EQT agreed to acquire Mabtech AB from IK Partners and Merieux Equity Partners. As of 2024, the company is led by its CEO, Phill Keefe. The company provides a wide range of immunoassay products, such as ELISpot kits, FluoroSpot kits, ELISA kits, and FociSpot assays.
Additionally, the firm offers Mabtech IRISTM 2 and Mabtech ASTORTM 2 readers, peptide pools, polyclonal stimuli, buffers, substrates, plates, and antibodies. The company generates revenue through the sale of its immunoassay products through its e-commerce platform.
Current Investors
IK Partners, Merieux Equity Partners
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Medical Equipment Distributors
Website
www.mabtech.com/
Verticals
E-commerce, HealthTech
Company Stage
Mature - Buyout
Total Amount Raised
Subscriber access only
Mabtech AB - timeline of key events
Mabtech AB - financials
| Fiscal Year Ended | Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 53,053,609 | 53,229,603 | 57,402,112 | 69,650,606 | 75,079,698 | 80,475,183 | 83,816,063 | 100,190,726 | 135,842,768 | 184,873,000 | 217,267,000 | - | - | - |
| % Revenue Growth (YoY) | - | 0.3% | 7.8% | 21.3% | 7.8% | 7.2% | 4.2% | 19.5% | 35.6% | 36.1% | 17.5% | - | - | - |
| EBITDA (USD) | 13,109,950 | 14,500,570 | 14,620,239 | 28,994,258 | 32,681,538 | 35,774,592 | 33,465,383 | 25,231,689 | 60,202,539 | 86,979,000 | 115,596,000 | - | - | - |
| Operating Income (USD) | 12,229,512 | 13,584,548 | 13,701,227 | 25,931,407 | 29,735,868 | 32,633,246 | 29,913,493 | 21,308,917 | 58,255,628 | 85,118,000 | 113,539,000 | - | - | - |
| Operating Margin | 23.1% | 25.5% | 23.9% | 37.2% | 39.6% | 40.6% | 35.7% | 21.3% | 42.9% | 46.0% | 52.3% | - | - | - |
| % EBITDA Margin | 24.7% | 27.2% | 25.5% | 41.6% | 43.5% | 44.5% | 39.9% | 25.2% | 44.3% | 47.0% | 53.2% | - | - | - |
| NET Income (USD) | 6,819,535 | 7,854,633 | 10,771,864 | 19,481,579 | 11,370,982 | 16,499,952 | 15,156,061 | 20,966,772 | 32,536,636 | 50,493,000 | (825,000) | - | - | - |
| % Net Margin | 12.9% | 14.8% | 18.8% | 28.0% | 15.1% | 20.5% | 18.1% | 20.9% | 24.0% | 27.3% | (0.4%) | - | - | - |
Mabtech AB - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Secondary Buyout | Completed | Mabtech AB | - | ||||||||
| Buyout | Completed | Mabtech AB | - |
Displaying 1 - 2 of 2
Mabtech AB - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.